FindTrial
Sign In

Intervention to reduce cardiac side effects due to anticancer drugs

Efficacy of ACE inhibitors in anthracycline-induced cardiotoxicity: a double blind placebo controlled randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/09/006174
Enrollment
90
Registered
2015-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Enalapril (ACE Inhibitor) : dose: 0.1 mg/kg/day route:oral frequency:daily total duration:6 months Control Intervention1: Placebo: daily for 6 months

Sponsors

Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of acute lymphoblastic leukemia, hodgkin and non hodgkin lymphoma 2. Patients receiving anthracyclines

Exclusion criteria

Exclusion criteria: 1. Relapsed disease 2. Previously treated disease 3. Pre existing cardiac disease 4. Pre existing renal disease 5. Pre existing hepatic disease

Design outcomes

Primary

MeasureTime frame
Decrease in left ventricular ejection fractionTimepoint: baseline, 6 months—

Secondary

MeasureTime frame
1. Level of cardiac biomarkers 2. Development of heart failure 3. Development of cardiac arrhythmias 4. Development of side effects: dizziness, hypotensionTimepoint: base line, 6 months—

Countries

India

Contacts

Public ContactVineeta Gupta

Department of Pediatrics, Institute of Medical Sciences

sunilkumarsinghdr@gmail.com08933055668

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026